These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 2025558)

  • 1. Relative efficacy of 335 and 365 nm radiation in photochemotherapy of psoriasis.
    Brücke J; Tanew A; Ortel B; Hönigsmann H
    Br J Dermatol; 1991 Apr; 124(4):372-4. PubMed ID: 2025558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PUVA erythemal sensitivity depends on plasma psoralen concentration and UVA sensitivity.
    Sakuntabhai A; Farr PM; Diffey BL
    Br J Dermatol; 1993 May; 128(5):561-5. PubMed ID: 8504050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The action spectrum between 320 and 400 nm for clearance of psoriasis by psoralen photochemotherapy.
    Farr PM; Diffey BL; Higgins EM; Matthews JN
    Br J Dermatol; 1991 May; 124(5):443-8. PubMed ID: 2039720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythemal and therapeutic response of psoriasis to PUVA using high-dose UVA.
    Speight EL; Farr PM
    Br J Dermatol; 1994 Nov; 131(5):667-72. PubMed ID: 7999598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Narrow band UVB (311 nm) phototherapy and PUVA photochemotherapy: a combination.
    Calzavara-Pinton P
    J Am Acad Dermatol; 1998 May; 38(5 Pt 1):687-90. PubMed ID: 9591811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis.
    Calzavara-Pinton P; Ortel B; Carlino A; Honigsmann H; De Panfilis G
    Exp Dermatol; 1992 Jul; 1(1):46-51. PubMed ID: 1344660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the dose-response relationship for psoralen-UVA erythema and UVB erythema.
    Cox NH; Farr PM; Diffey BL
    Arch Dermatol; 1989 Dec; 125(12):1653-7. PubMed ID: 2589859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of treatment frequency and UVA dose does not substantially compromise the antipsoriatic effect of oral psoralen-UVA.
    Legat FJ; Hofer A; Quehenberger F; Kahofer P; Kerl H; Wolf P
    J Am Acad Dermatol; 2004 Nov; 51(5):746-54. PubMed ID: 15523353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach.
    Collins P; Wainwright NJ; Amorim I; Lakshmipathi T; Ferguson J
    Br J Dermatol; 1996 Aug; 135(2):248-54. PubMed ID: 8881668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythema action spectrum of topical 8-methoxypsoralen-sensitized skin re-evaluated: implications for routine clinical practice.
    Al-Ismail D; Edwards C; Anstey AV
    Br J Dermatol; 2016 Jan; 174(1):131-5. PubMed ID: 26383592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large increments in psoralen-ultraviolet A (PUVA) therapy are unsuitable for fair-skinned individuals with psoriasis.
    Kirby B; Buckley DA; Rogers S
    Br J Dermatol; 1999 Apr; 140(4):661-6. PubMed ID: 10233317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of narrow-band (311 nm) UVB and broad-band UVA after oral or bath-water 8-methoxypsoralen in the treatment of psoriasis.
    Ortel B; Perl S; Kinaciyan T; Calzavara-Pinton PG; Hönigsmann H
    J Am Acad Dermatol; 1993 Nov; 29(5 Pt 1):736-40. PubMed ID: 8227546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Half-side comparison of erythemogenic versus suberythemogenic UVA doses in oral photochemotherapy of psoriasis.
    Tanew A; Ortel B; Hönigsmann H
    J Am Acad Dermatol; 1999 Sep; 41(3 Pt 1):408-13. PubMed ID: 10459114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PUVA therapy for psoriasis: comparison of oral and bath-water delivery of 8-methoxypsoralen.
    Lowe NJ; Weingarten D; Bourget T; Moy LS
    J Am Acad Dermatol; 1986 May; 14(5 Pt 1):754-60. PubMed ID: 3711379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between plasma psoralen concentration and psoralen-UVA erythema.
    Mclelland J; Fisher C; Farr PM; Diffey BL; Cox NH
    Br J Dermatol; 1991 Jun; 124(6):585-90. PubMed ID: 2064944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bath-5-methoxypsoralen-UVA therapy for psoriasis.
    Calzavara-Pinton PG; Zane C; Carlino A; De Panfilis G
    J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):945-9. PubMed ID: 9204060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of psoriasis to twice weekly PUVA.
    Sakuntabhai A; Sharpe GR; Farr PM
    Br J Dermatol; 1993 Feb; 128(2):166-71. PubMed ID: 8457450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Principles of photochemotherapy and of the determination of the initial dosage of long-wave ultraviolet rays in the photochemotherapy (PUVA) method of treatment].
    Vladimirov VV
    Vestn Dermatol Venerol; 1981 Jan; (1):19-24. PubMed ID: 7210865
    [No Abstract]   [Full Text] [Related]  

  • 19. Glutathione S-transferase genotype is associated with sensitivity to psoralen-ultraviolet A photochemotherapy.
    Ibbotson SH; Dawe RS; Dinkova-Kostova AT; Weidlich S; Farr PM; Ferguson J; Wolf CR; Smith G
    Br J Dermatol; 2012 Feb; 166(2):380-8. PubMed ID: 21967523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsoriatic, erythematogenic, and Langerhans cell marker depleting effect of bath-psoralens plus ultraviolet A treatment. Comparison of 8-methoxypsoralen and trimethylpsoralen photosensitization.
    Koulu LM; Jansén CT
    J Am Acad Dermatol; 1988 May; 18(5 Pt 1):1053-9. PubMed ID: 2968374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.